Companies › Carnot Laboratories
1 active drug program in 6 registered trials: 3 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Cardiovascular, Gastroenterology, Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tegoprazan Potassium-transporting ATPase blocker | ATP4A, ATP4B | Phase 4 | Gastroesophageal Reflux Disease; Helicobacter Pylori Infection Chronic Gastrit; Coronary Artery Disease; Ischemic Stroke … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06523764 | Tegoprazan | Phase 4 | Helicobacter Pylori Infection Chronic Gastrit | Infectious disease | Aug 2025 |
| NCT07242456 | Tegoprazan | Phase 2 | Helicobacter Pylori Infection | Infectious disease | Nov 2025 |
| NCT06991348 | Tegoprazan | Phase 4 | Gastroesophageal Reflux Disease | Gastroenterology | Nov 2025 |
| NCT07708545 | Tegoprazan | Phase 2 | Peptic Ulcer Bleeding | Gastroenterology | Dec 2026 |
| NCT07687706 | Tegoprazan | Phase 3 | Ischemic Stroke | Neurology | Jun 2027 |
| NCT04416581 | Tegoprazan | Phase 4 | Coronary Artery Disease | Cardiovascular | Dec 2027 |
Phathom Pharmaceuticals Il-Yang Pharm. AstraZeneca Cinclus Pharma Holding
Phathom Pharmaceuticals Cinclus Pharma Holding Khondrion Shin Poong Pharmaceutical CSPC Mingfule Pharmaceutical (Guangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.